Analysis Tools
mortality/aging
|
• most mice die within 2 months following doxycycline treatment
|
hematopoietic system
|
• decrease in the frequency of bipotential megakaryocytic-erythroid cells and preGM/GMP progenitor cells at 7 weeks after doxycycline treatment
|
|
• by 10 days after doxycycline treatment
• absolute numbers of all hematopoietic stem and progenitor cells are reduced at 7 weeks after doxycycline treatment
|
|
• seven weeks after doxycycline treatment
|
|
• decrease in the frequency or proerythroblasts in the bone marrow by 10 days after doxycycline treatment
|
macrocytosis
(
J:179085
)
|
• seven weeks after doxycycline treatment
|
|
• two weeks after doxycycline treatment
|
|
• two and seven weeks after doxycycline treatment
|
|
• seven weeks after doxycycline treatment
|
|
• seven weeks after doxycycline treatment
|
|
• two and seven weeks after doxycycline treatment
|
|
• two weeks after doxycycline treatment
|
|
• preMegE and preCFU-E/CFU-E progenitors show impaired proliferation and increased apoptosis following doxycycline treatment
|
growth/size/body
|
• following doxycycline treatment
|
digestive/alimentary system
|
• occasional dilated glands in the large intestine and colon
|
immune system
|
• seven weeks after doxycycline treatment
|
|
• two and seven weeks after doxycycline treatment
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Diamond-Blackfan anemia | DOID:1339 |
OMIM:PS105650 |
J:179085 | |
